Overview
Arda Therapeutics develops targeted therapies using single-cell data to treat diseases. It identifies disease-causing (pathological) cells by analyzing patients' cells at the single-cell level and designs therapies that eliminate only those harmful cells, minimizing harm to healthy cells. The company operates in precision medicine and sells work to healthcare providers, pharmaceutical companies, and research institutions through a B2B model. Revenue comes from partnerships with pharma companies, licensing its technology, and providing specialized research services. Unlike others, Arda centers its platform on single-cell analysis to guide therapy design, enabling highly specific treatments rather than general approaches. The goal is to bring precise, effective therapies to the market by collaborating with larger healthcare players and researchers to accelerate development and deployment."} ?-? ))){
Work here?Claim your company
Simplify's take
What believers are saying
- Arda raised $43 million Series A on October 9, 2024, extending runway.
- A 2026 career posting for principal scientist shows active hiring in R&D.
- The company remains active in San Carlos, with support from high-quality biotech investors.
What critics are saying
- Arda posted no pipeline data on November 10, 2026, signaling preclinical execution risk.
- Only one San Carlos opening exists, suggesting limited scale and slow development momentum.
- If lead programs miss clinic entry by 2027, platform credibility weakens fast.
What makes Arda Therapeutics unique
- Arda targets pathogenic cells directly, not broad pathways, using single-cell discovery.
- Andreessen Horowitz, GV, Two Sigma, and Eli Lilly back the platform.
- Scott Turner joined as chief scientific officer on October 9, 2024.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards